1.STUDY ON DIETARY LIPID INTAKES IN CHINESE RESIDENTS
Jian ZHANG ; Chunrong WANG ; Junquan GAO ; Xiaowei LI ; Junshi CHEN
Acta Nutrimenta Sinica 1956;0(03):-
Objective: To study the amount of fat, cholesterol and fatty acid intake in China and provide the basic material for dietary guidance. Methods: Two areas were selected both in North and South China and each area included 3 provinces, or municipality or autonomous region. Three representative survey sites were selected in each province, or municipality or autonomous region. Dietary survey was conducted by the method of weighing and recording and cooking method was also recorded. The amount of food consumption was calculated as standard person (adult male, light physical activity). All foods were gathered as 12 kinds of foods, and each kind of food was cooked and then mixed. The content of fat and fatty acid was analyzed for 8 kinds of foods and the content of cholesterol was analyzed for 4 kinds of foods. The intake of fat, fatty acid and cholesterol per capita was calculated. Results: The amount of fat intake among North I, North II, South I, South II was 70.5 g, 46.5 g, 58.7 g, 71.0 g respectively and the amount of cholesterol intake was 329.6 mg, 128.5 mg, 400.9 mg, 306.0 mg respectively. The main source of dietary fat was from meat and vegetables. Egg was the main source of dietary cholesterol and meat and egg were both the main source of dietary cholesterol in south II area. About 90% of saturated fatty acid was palmitic acid and stearic acid and 90% of monounsaturated fatty acid was oleic acid. Linoleic acid was the principal n-6 polyunsaturated fatty acid and linolenic acid was the principal n-3 polyunsaturated fatty acid. The ratio of S∶M∶P in North I was 1∶1.1∶1, in North II was 1∶1.6∶1.3, in South I was 1∶1.6∶1.3 and in South II was 1∶1.5∶1. Conclusion: The amount of fat intake and fatty acid profile was quite different among different areas and the dietary guidance should be more pertinent The current cholesterol intake was more than dietary guidance in most areas. In addition to egg, meat was also an important source of cholesterol.
2.DETERMINATION OF TOTAL RARE-EARTH METALS IN FOOD BY SPECTROPHOTOMETRIC METHOD
Dezhao SU ; Junquan GAO ; Fengying SUNG ; Huaizhou WANG
Acta Nutrimenta Sinica 1956;0(02):-
A simple spcctrophotometric method for determination of total rare-earth metals in food is presented. Weigh 5 gm of dry sample in a dish. After soaking the sample more than half an hour with 10 ml 3N H2SO4, evaporate to dryness on a hot plate and ash at 600℃. Dissolve the ash in 1 ml 6N HCl, and evaporate to dryness. Dissolve the residue in 2 ml water, and transfer it to a 10 mi-graduated tube. Wash the dish repeatedly with small amount of water. Transfer the washings to the same tube, and dilute to 10 ml with water. Pipette two portions of aliquots of 4 ml sample solution to two 10ml graduated tubes in which 2 ml of HCOOH-NH3 buffer (pH 3.7) is added. After mixing, add 1 ml each of 10% sulphosalicylic acid solution and 5% ascorbic acid solution. Make volume to 8 ml with water. Mix thoroughly. After 10 minutes, add 1 ml 15% alcoholic diphenylguani-dine solution, mix and add 1 ml 0.025% arsenazo Ⅲ &K solution. Mix, and measure the optical density at 680, 660 and 640 nm against a reagent blank solution. Calculate the total rare-earth metals content with a calibration curve. The sensitivity of the method is 0.01 ?g/ml and the detection limit is 0.05ppm (5 gm of sample). The average recovery of added TRExOy is 91.9% (n = 14).
3.Long-term outcomes of intracavitary hyperthermia in combination with radiotherapy for locally advanced uterine cervical cancer
Qingsong PANG ; Ruiying LI ; Qiuling GAO ; Junquan YANG ; Fengtong LI ; Li ZHU ; Xue MEI ; Haipan WANG ; Ping WANG
Chinese Journal of Radiation Oncology 2008;17(6):454-457
Objective To evaluate the long-term clinical efficacy and toxicities of combined intracavitary hyperthermia and radiotherapy fur locally advanced uterine cervical cancer. Methods 310 patients with locally advanced uterine cervical cancer were assigned into intracavitary hyperthermia + radiotherapy group(TRT, 181 patients) and external-beam radiotherapy + traditional intracavitary radiation group (RT,129 patients). The external-beam radiotherapy were given with 60Co γ-my or 6-8 MV X-ray in traditional fractionation. In TRT group,radiotherapy was 40 Gy using the anterior-posterior pelvic fields and additional 20-25 Gy using the lateral fields. Hyperthermia was delivered by the 915 MHz microwave hyperthermia device within 15-60 min after external radiotherapy for 10-12 times(40 min each time,1-2 times per week). The temperature of tumor surface was 46-47℃. In the RT group, the external-beam radiotherapy of 40 Gy was delivered using the anterior-posterior pelvic fields. The intracavity radiotherapy of radium was delivered before 1989 ,with 50 mg radium in the vagina and 30 mg in uterine cavity for 24 hours ,weekly for 3 times to a total dose of 7200 mg·h. After 1989,intraeavity radiotherapy of 192Ir was delivered to a total dose of 30-36 Gy to point A in 5-6 Gy fractions,2 fractions per week. Results The 5-year survival of patients in TRT group and RT group was 67.4% versus 52.1% for stage Ⅱ disease (χ2=7.55,P=0.006), and 60.0% vemus32.3% forstage Ⅲ (χ2=7.06,P=0.007) . The 10-year survival was46.5% versus42.6% for stage Ⅱ (χ2=3.90,P=0.058), and 43.7% versus 20.6% for stage Ⅲ(χ2=17.28,P=0.000). Cox regression analysis showed that the tumor stage(P=0.023) and intracavitary hyperthermia( P=0.019) were prognostic factors. According to the RTOG criteria, the rate of mild to moderate late side effects of rectum and bladder in TRT and RT group was 17.7% and 33.1%, respectively (χ2=9.18, P=0.002). Rectovaginal fistula was developed in5 patients(3.9% ) in RT group and I patient (0.6%) in TRT group(χ2= 4.38,P=0.036). Conclusions The long-term survival of patients with stage Ⅲ uterine cervical cancer is better of TRT group than RT group. The TRT is well tolerated and the late toxicity rate is obviously low. It is necessary to carry out large randomized clinical trials to confirm these outcomes.
4.A phase Ⅲ multicenter trial of radiosensitizing effect and safety of sodium glycididazole in thoracic esophegeal squamous carcinoma
Shangbin QIN ; Yadi WANG ; Junquan YANG ; Xiaohu WANG ; Haibin LI ; Zhiyong YANG ; Hong YU ; Xueying LI ; Xianshu GAO
Chinese Journal of Radiation Oncology 2012;21(5):426-429
ObjectiveTo evaluate the efficacy and clinical safety of sodium glycididazole (CMNa)in thoracic esophageal squamous carcinoma.Methods From June 1,2008 to October 13,2009,66pathologically proved thoracic esophageal squamous carcinoma (stage Ⅱa-Ⅲ,stage Ⅳ with metastases only in supraclavicular lymph nodes,by AJCC 6th ed) were randomized into radiotherapy plus CMNa (A) or radiotherapy plus placebo (B) group.Radiotherapy was given by conventional schedule:1.8-2.0 Gy per fraction,5 times per week to a total dose of 66 Gy/6.6-7.2w.CMNa was given intravenously 800 mg/m2 3 times a week in solution of 100 ml saline within 30 minutes.Radiotherapy was started 30-60 minutes after completion of infusion.Patients of Group B received placebo in saline solution.A total of 66 patients were enrolled ( Group A:32 ; Group B:34 ),and four patients were unanalyzable,remaining 31 patients in each Group.Baseline factors were balanced.ResultsFollow-up rate was 97%.Group A vs.Group B:the overall response rate was 93.5% vs.67.7% ( x2 =6.61,P =0.01 ),2-year overall survival was 39.9% vs.29.9% ( x2 =0.62,P =0.433 ),2-year cancer specific survival was 43.1% vs.26.8% ( x2 =0.30,P =0.878),and 2-year progression-free survival was 30.1% vs.27.9% ( x2 =0.02,P =0.586).No severe side effects observed.All patients tolerated CMNa infusion well.Conclusions CMNa is tolerable and effective as a hypoxic radiosensitizer,and its combination with radiotherapy can improve short term effect.However,survival is not improved within our follow-up period.
5.A case of type 1 diabetes caused by gastric cancer treated with Sintilimab
Yihan GAO ; Jingyu CHEN ; Haoyu FU ; Junquan YANG
Clinical Medicine of China 2024;40(1):70-72
Immune checkpoint inhibitors (ICIs) are currently used in the treatment of various tumors and play an important role in tumor treatment, resulting in many adverse reactions related to the immune system. Type 1 diabetes (T1DM) is a rare endocrine system complication, which is rarely reported at present. We report a case of T1DM after using ICIs to treat gastric cancer. The patient was a 34 year old male who developed diabetes ketoacidosis after 206 days of sintilimab monoclonal antibody use, with fasting blood glucose of 15.78 mmol/L and glycosylated hemoglobin of 8.6%. Islet related antibody: Glutamate decarboxylase antibody: 119.2 IU/mL; Insulin antibody:<2 IU/L. Fasting insulin: 0.21 mU/L; Fasting C-peptide: 0.12 μg/L. Through the analysis of patients' clinical data, it aims to improve clinicians' understanding of immune related type 1 diabetes and provide ideas for correct diagnosis and treatment.